Funding Gap? Academic health center leaders report managed care squeeze

The federal government should give more money to medical schools and teaching hospitals, two recent reports recommend. But managers of academic health centers shouldn't expect such a windfall, says one administrator. "I would not risk the viability of my own institution by waiting for federal funds," comments Ralph Snyderman, chancellor for health, executive dean, and president and CEO, Duke University Health Systems Inc., at Duke University Medical Center. Snyderman agrees with two recent rep

Written byPaul Smaglik
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The federal government should give more money to medical schools and teaching hospitals, two recent reports recommend. But managers of academic health centers shouldn't expect such a windfall, says one administrator.

"I would not risk the viability of my own institution by waiting for federal funds," comments Ralph Snyderman, chancellor for health, executive dean, and president and CEO, Duke University Health Systems Inc., at Duke University Medical Center. Snyderman agrees with two recent reports showing that academic health centers in competitive markets have less money for internally funded research than those in less competitive markets. However, instead of anticipating a federal fix, researchers at medical schools who find their research budgets squeezed by managed care should start planning. Managers at Duke reevaluated their business in 1991. "We had a market share of only 3 percent in one of the wealthiest, fastest growing counties in the country," Snyderman recalls. They responded ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies